TP53 Mutations Predict for Poor Survival in ALK Rearrangement Lung Adenocarcinoma Patients Treated with Crizotinib

被引：0

作者：

Wang, W. ^{[1
]}

Xu, C. ^{[2
]}

Chen, Y. ^{[2
]}

Zhuang, W. ^{[3
]}

Lin, G. ^{[3
]}

Chen, X. ^{[4
]}

Wu, B. ^{[3
]}

Huang, Y. ^{[3
]}

Chen, R. ^{[5
]}

Guan, Y. ^{[5
]}

Yi, X. ^{[5
]}

Fang, M. ^{[1
]}

Lv, T. ^{[6
]}

Chen, G. ^{[2
]}

Song, Y. ^{[6
]}

机构：

[1] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China

[2] Fujian Prov Canc Hosp, Pathol, Fuzhou, Fujian, Peoples R China

[3] Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Fujian, Peoples R China

[4] Fujian Prov Canc Hosp, Thorac Surg, Fuzhou, Fujian, Peoples R China

[5] Geneplus Beijing, Beijing, Peoples R China

[6] Nanjing Univ, Sch Med, Jinling Hosp, Dept Resp Med, Nanjing, Jiangsu, Peoples R China

来源：

关键词：

TP53; ALK; crizotinib;

D O I：

10.1016/j.jtho.2017.09.656

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-002

引用

页码：S1892 / S1892

页数：1